logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

AT ASCO Gilead Sciences and Yescarta ® By Acquiring Kite Pharma   Gilead Sciences( GILD ) gained Kite’s CAR T technology and its FDA approved therapy Yescarta.  At the ASCO 2019 two new analyses were presented from the ZUMA-1 clinical...

Read More

June 6, 2019

0

Why Vertex's and CRISPR Therapeutics’ Stocks Are Rallying

Vertex and CRISPR Therapeutics While some groups are doubting the gene editing capability of CRISPR gene editing Vertex’s ( VRTX ) scientists enjoyed what they experienced during their clinical collaboration with CRISPR Therapeutics ( CRSP ), until now. Vertex felt...

Read More

June 7, 2019

0

Gilead Sciences and Galapagos NV: Good News from Filgotinib in Ulcerative Colitis

Gilead Sciences and Galapagos NV Announce Good News from Filgotinib Trial Gilead Sciences ( GILD ) and Galapagos NV ( GLPG ) announced positive topline results from the SELECTION trial - a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the...

Read More

May 21, 2020

0

Cassava Sciences, Moderna and Sorrento Therapeutics All Have News

News from Cassava Sciences, Moderna and Sorrento Therapeutics  Cassava Sciences  Cassava Sciences ( SAVA ) announced that clinical results of its Phase 2b study of sumifilam have been selected as a late-breaking oral presentation by the 13th international conference on...

Read More

September 30, 2020

0

Encouraging Results From Nektar's Product BEMPEG: NKTR-214 In Combination with the Checkpoint Inhibitor Nivolumab

Nektar Therapeutics Nektar Therapeutics ( NKTR ) announced the publication of Phase 1 clinical data for its immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) + nivolumab, in Cancer Discovery -  a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer...

Read More

May 22, 2020

0

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Nektar Announced Results for NKTR-358  During an oral session at the Annual European Congress of Rheumatology ( EULAR ) 2019, in Madrid , Nektar Therapeutics ( NKTR ) announced results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358 ...

Read More

June 13, 2019

0

The FDA Lifted the Clinical Hold on Solid Biosciences' IGNITE DMD Phase 1/2 Trial Sending the Stock Price Over 131%

Solid Biosciences Clinical Hold on IGNITE DMD is Lifted by the FDA Solid Biosciences ( SLDB ) - a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that the U.S. FDA has lifted the clinical...

Read More

October 1, 2020

0

Why Sonoma Pharmaceuticals and Adaptimmune Stock Prices Skyrocketed

Sonoma Pharmaceuticals and MicroSafe Group, Dubai Sonoma Pharmaceuticals ( SNOA ) develops stabilized hypochlorous acid (HOCl) products for a wide range of applications including: wound care, eye care and dermatological conditions. Together with MicroSafe Group, Dubai, announced the receipt of...

Read More

May 29, 2020

0

News From Four Biotech Companies and Several Treatments

AstraZeneca and Merck PARP Inhibitor Lynparza The AstraZeneca ( AZN ) and Merck ( MRK )   PARP inhibitor Lynparza (olaparib) has been granted approval in Europe for first-line maintenance monotherapy for BRCA 1 & 2 mutated advanced ovarian cancer...

Read More

June 19, 2019

0

Compugen Adds an Immuno-Oncology Pioneer to its Scientific Advisory Board. See Also: The New War Against Aging

Compugen New Addition, Dr. Nils Lonberg, PhD. Compugen ( CGEN ) announced the addition of Nils Lonberg, Ph.D., to its Scientific Advisory Board (SAB). Dr. Lonberg is a pioneer in the field of immuno-oncology and has more than 30 years...

Read More

October 8, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 97
  • 98
  • 99
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy